Literature DB >> 7205633

The interaction of lisuride, an ergot derivative, with serotonergic and dopaminergic receptors in rabbit brain.

M R Rosenfeld, M H Makman.   

Abstract

The interaction of lisuride (Lysenyl, Spofa), an ergot derivative, with serotonergic and dopaminergic receptors and with adenylate cyclase was studied in homogenates of rabbit brain. In frontal cortex, lisuride interacts with serotonin receptors as shown by its ability to compete with [3H]serotonin, [3H]spiroperidol and [3H]lysergic acid diethylamide for their receptor binding sites, with respective IC50 values of 14, 1.0 and 3.7 nM. The IC50 for displacement of [3H]spiroperidol by lisuride in frontal cortex was increased by the GTP analog, 5'-guanylylimidodiphosphate, indicating an agonist-like interaction. Lisuride is extraordinarily potent in stimulating serotonin-sensitive adenylate cyclase in this brain region, with maximal stimulations occurring at 0.1 nM lisuride. In caudate nucleus, lisuride interacted with both serotonergic and dopaminergic receptor sites as labeled by [3H]serotonin, [3H]lysergic acid diethylamide and [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, with IC50 values ranging from 2.0 to 7 nM. Lisuride did not stimulate adenylate cyclase in caudate nucleus. In summary, lisuride is a very potent stimulator of serotonin-sensitive adenylate cyclase in rabbit frontal cortex and can interact with serotonin and dopamine receptor binding sites in rabbit cortex and caudate nucleus.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7205633

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus.

Authors:  R Markstein; D Hoyer; G Engel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-08       Impact factor: 3.000

2.  Some anticonvulsant drugs alter monoamine-mediated behaviour in mice in ways similar to electroconvulsive shock; implications for antidepressant therapy.

Authors:  A R Green; P Johnson; J A Mountford; V L Nimgaonkar
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

3.  5-HT2 receptor characteristics in frontal cortex and 5-HT2 receptor-mediated head-twitch behaviour following antidepressant treatment to mice.

Authors:  G M Goodwin; A R Green; P Johnson
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

4.  Antidepressant treatments: effects in rodents on dose-response curves of 5-hydroxytryptamine- and dopamine-mediated behaviours and 5-HT2 receptor number in frontal cortex.

Authors:  A R Green; D J Heal; P Johnson; B E Laurence; V L Nimgaonkar
Journal:  Br J Pharmacol       Date:  1983-10       Impact factor: 8.739

5.  Increased 5-HT2 receptor number in brain as a probable explanation for the enhanced 5-hydroxytryptamine-mediated behaviour following repeated electroconvulsive shock administration to rats.

Authors:  A R Green; P Johnson; V L Nimgaonkar
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

6.  Locomotor effects of lisuride: a consequence of dopaminergic and serotonergic actions.

Authors:  H Fink; R Morgenstern
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Sodium ion modulates D2 receptor characteristics of dopamine agonist and antagonist binding sites in striatum and retina.

Authors:  M H Makman; B Dvorkin; P N Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.